ClinicalTrials.gg
RecruitingNCT07213531ENVISAGEUpdated Oct 9, 2025

Enhanced Valves Interventions and Safe AI Generated End Results

An observational study in Heart Valve Disease, TAVI and M-TEER, sponsored by Montreal Heart Institute. Recruiting at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Montreal Heart Institute · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
21,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Heart Valve Diseases with a site in France — 16 open to participants now, 22 under way, 1 of them phase 3. Heart Valve Diseases · France.

Planned enrollment
Largest of 17
21,000 · median 800
Started
2024
with 5 others
Observational
17 of 48
10 open now
Primary completion
2028-05
later than 13 of 21 live
Registered
48th of 48
by date

Among the 48 studies in Heart Valve Diseases with a site in France, this one has the largest planned enrollment of the 17 observational ones that give a count, is one of 6 that started in 2024, is one of 17 observational ones, reaches primary completion later than 13 of the 21 other live ones, and was the 48th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

16 of the 48 studies in Heart Valve Diseases with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Heart Valve Diseases with a site in France, or all of them as a file.
02

Study summary

This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.

Read the detailed description

The ENVISAGE study is a non-interventional, retrospective research study designed to validate an artificial intelligence (AI)-based framework for the automated analysis of cardiac imaging data, including multi-slice cardiac computed tomography (CT) and transesophageal echocardiography (TEE). The primary objective is to predict the success of transcatheter heart valve interventions, including aortic, mitral, and tricuspid valve interventions (TAVI, TMVI, M-TEER, T-TEER). The AI framework developed in this study will rely on deep learning algorithms, particularly convolutional neural networks (CNNs) and other advanced models, to automatically segment critical anatomical structures and perform accurate measurements of these structures from CT and TEE images. These measurements will then be combined with pre-interventional clinical data to optimize patient selection and intervention planning, as well as to predict surgical outcomes with high accuracy. AI will also aim to reduce human error and inter-observer variability in the interpretation of cardiac images, which could significantly improve clinical outcomes.

03

Conditions studied

  • Heart Valve Disease
  • TAVI
  • M-TEER
  • TTVI
  • TMVI
  • T-TEER
  • Mitraclip
  • TriClip

Browse trials for

Keywords

  • Medical imaging
  • CT
  • Artificial intelligence
  • M-TEER
  • T-TEER
  • TAVI
  • TMVI
  • valvulopathy
  • predictive algorithms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with heart valve disease eligible for transcatheter interventions (TAVI, M-TEER, TMVI, TTVI).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who have reached the age of legal majority under local laws.

  • For TAVI group: All patients who have had TAVI with a third generation transcatheter heart valve (THV), with an available pre-procedural optimal quality CT scan as defined by an - gating CT with:

    1. five to ten image volumes at cardiac phases from 5% to 95% R-R
    2. 0.625 mm slice thickness
    3. 0.625 mm spacing between slices
    4. 0.88 mm in-plane pixel spacing
  • For TMVI group: Patients who have had a TMVI with a dedicated device and screen failures, with an available optimal quality CT scan.
  • For TTVI group: Patients who have had a TTVI with a dedicated device and screen failures, with an available optimal quality CT scan.
  • For M-TEER: All patient who have had a M-TEER with 1) G4 or newer iteration of MitraClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Mitral valve, frame per second equal or higher than 40 frames per second, acceptable 3D reconstructions.
  • For T-TEER: All patient who have had a T-TEER with G4 or newer iteration of TriClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Tricuspid valve, frame per second equal or higher than 40 frames per second, acceptable transgastric image with acceptable 3D reconstructions.

Exclusion criteria

Exclusion Criteria:

  • For TAVI group: Valve-in-valve procedures
  • For TMVI group: Valve-in-valve and valve-in-ring procedures
  • For TTVI: Valve-in-valve and valve-in-ring procedures
  • For M-TEER: G3 or older MitraClip, G1 Pascal
  • For T-TEER: G3 Triclip, G1 Pascal
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
21,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • TAVI

    All patients who have had TAVI with a third generation transcatheter heart valve (THV). Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.

    Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms

  • TMVI

    Patients who have had a TMVI with a dedicated transeptal device and screen failures. Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.

    Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms

  • TTVI

    Patients who have had a TTVI with a dedicated device and screen failures. Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.

    Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms

  • M-TEER

    All patients who have had a M-TEER with 1) G4 or newer iteration of MitraClip or 2) G2 or newer iteration of Pascal. Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.

    Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms

  • T-TEER

    All patients who have had a T-TEER with G4 or newer iteration of TriClip or 2) G2 or newer iteration of Pascal. Medical imaging data (CT, TEE) and preoperative clinical data will be collected for analysis.

    Diagnostic Test: Medical imaging analysis via artificial intelligence algorithms

Interventions

  • Diagnostic testMedical imaging analysis via artificial intelligence algorithms

    Development of AI algorithms based on pre-procedural imaging annotations and clinical informations to predict the transcatheter procedural outcomes

06

What researchers measure

Primary outcomes

  1. Accuracy of transcatheter AI predictions

    Validation of artificial intelligence algorithms for automatic segmentation of anatomic structures and imaging measurements, and prediction of the success of transcatheter interventions. Output of AI algorithm: * Sizes, types, and number of devices to be implanted * Device success * Percentage risk of permanent pacemaker implantation (for TAVI and TTVI) * Percentage risk of 30-day (para)valvular regurgitation for TAVI, and residual regurgitation for M-TEER and T-TEER * Single leaflet detachment for M-TEER and T-TEER * Left ventricular outflow tract obstruction for TMVI. Key success indicators: * First, independent retrospective validation dataset AI algorithms predict procedural outcome with \>90% accuracy and low inter-reader observer variability when compared to measured procedural outcome. * Second independent retrospective dataset, perform a study to validate AI algorithms with \>90% accuracy and low inter-reader observer variability when compared to measured procedural outcome.

    Time frame: Preoperative phase: automated segmentation and measurements compared with manual assessments; Postoperative phase at day 30: comparison of predicted results with actual clinical patient outcomes.

Secondary outcomes

  1. Performance of AI algorithms in CT and TEE image analysis

    Development and evaluation of AI algorithm training platform for data analysis of patients undergoing transcatheter valve procedures. Comparison of AI model performance with existing benchmarks and manual analyses

    Time frame: Through study completion, an average of 2 years (retrospective analysis and validation of algorithms).

Other outcomes

  1. AI-based discovery of clinical knowledge for patient selection

    Comparison of AI's ability to standardize patient selection, treatment planning and clinical outcomes with traditional methods. Assessment of accuracy in predicting patient outcomes and reducing procedure-specific complications.

    Time frame: Baseline (pre-procedural) and post-procedural (day 90) analysis

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for May 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 9, 2025
StartActual
May 1, 2024
Primary completionEst.
May 2028
CompletionEst.
May 2029
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07213531
Collaborators
Centre Hospitalier Universitaire de Bordeaux, FRANCE, Materialise, Pie Medical Imaging, Clinique Pasteur Toulouse, Centre Cardiologique du Nord, Rennes University Hospital, San Raffaele University Hospital, Italy, Istituto clinico Città di Brescia, Unity Health Toronto, University Hospital, Marseille, University Hospital, Lille, Hospitaux Universitaires Paris Sud, Montefiore Medical Center, University Medical Center Mainz, Universitätsklinikum Hamburg-Eppendorf, Vancouver Hospital
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
May 1, 2024
Primary completion
May 2028 (estimated)
Completion
May 2029 (estimated)
Last update
Oct 9, 2025

Study contacts

Thomas Modine, MD, PhD
Contact
thomasmodine@gmail.com
+33(0)5 25 377541
Walid Ben Ali, MD, PhD
Contact
dr.walidbenali@gmail.com
+1 5145611037
Thomas Modine, MD, PhD
principal investigator · University Hospital Bordeaux, France
Walid Ben Ali, MD, PhD
principal investigator · Montreal Heart Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion